Literature DB >> 8961591

Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management.

J R Sullivan1, A Watson.   

Abstract

There is growing evidence that the final common pathway of toxic epidermal necrolysis (TEN) is mediated by the cellular immune system which targets drug altered epithelial antigens. This provides a rationale for immunosuppressive therapy. The ideal regimen for quickly turning off epidermal damage in TEN has not yet been determined and the use or benefit of routine immunosuppression remains highly controversial. This article reviews recent advances in the pathogenesis of TEN along with the theoretical benefits of early immunosuppressive treatment in severe cases, specifically utilizing cyclosporin. We describe a 29-year-old woman with TEN due to the anticonvulsant lamotrigine whose successful management included intravenous cyclosporin. The extension of her lesions ceased within 24 hours of initiating cyclosporin (day 7 of her admission). Complications included: scarring alopecia; Enterococcus faecalis septicaemia due to an infected central line; and ulceration and squamous metaplasia of conjunctivae. The potential role of lamotrigine as a cause of TEN is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961591     DOI: 10.1111/j.1440-0960.1996.tb01057.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  8 in total

Review 1.  Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management.

Authors:  Alberto Verrotti; Daniela Trotta; Carmela Salladini; Francesco Chiarelli
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 3.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

4.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

5.  Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database.

Authors:  Maria Tengstrand; Kristina Star; Eugène P van Puijenbroek; Richard Hill
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

6.  Update on the management of antibiotic allergy.

Authors:  Bernard Yu-Hor Thong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 7.  Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.

Authors:  Audrey Jacobsen; Bayanne Olabi; Annie Langley; Jennifer Beecker; Eric Mutter; Amanda Shelley; Brandon Worley; Timothy Ramsay; Arturo Saavedra; Roses Parker; Fiona Stewart; Jordi Pardo Pardo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-11

Review 8.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.